GSE151412 In vivo screen identifies LXR agonism potentiates sorafenib killing of hepatocellular carcinoma
Conclusions: We have completed a novel drug resistance screen in vivo, and identified that LXR agonism potentiates the efficacy of sorafenib in treating HCC.
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research
More News: Cancer & Oncology | Carcinoma | Databases & Libraries | Genetics | Hepatocellular Carcinoma | Liver | Liver Cancer | Urology & Nephrology